Spravato Treatment for Adults With Treatment-Resistant Depression
Depression can continue even after medication, therapy, lifestyle changes, and repeated treatment attempts. SPRAVATO Treatment may be an option for eligible adults whose depression has not improved enough with previous antidepressant treatment.
SPRAVATO is the brand name for esketamine nasal spray, a prescription medication used under healthcare provider supervision. It is not a take-home nasal spray, a general wellness treatment, or the same thing as compounded ketamine products. Treatment requires clinical evaluation, safety screening, supervised administration, and monitoring after every session.
SPRAVATO evaluation and treatment planning at Lotus Psychiatry & Wellness Side Effects and Risks to Discuss Before Treatmentis provided within a psychiatric practice led by Mustafa Pirzada, M.D., a board-certified child, adolescent, and adult psychiatrist.
Request a SPRAVATO Treatment Evaluation
Request Consultation
Request a SPRAVATO Treatment Consultation Email: info@lotuspsychiatryandwellness.com
What Is SPRAVATO Treatment?
SPRAVATO Treatment is supervised medical treatment using SPRAVATO, an esketamine nasal spray. SPRAVATO is a non-competitive N-methyl-D-aspartate receptor antagonist, also called an NMDA receptor antagonist. The exact way esketamine improves depressive symptoms is not fully understood, but it works differently from many traditional oral antidepressants.
SPRAVATO is indicated for adults with treatment-resistant depression, either as monotherapy or with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, in conjunction with an oral antidepressant.
SPRAVATO is not meant for every person with depression. A qualified provider must review diagnosis, treatment history, medication history, medical risks, safety needs, and treatment goals before deciding whether SPRAVATO is appropriate.
SPRAVATO Treatment at Lotus Psychiatry & Wellness
At Lotus Psychiatry & Wellness, SPRAVATO is part of the clinic's advanced depression treatment options. Patients can expect a structured process that may include consultation, pre-assessment, safety screening, treatment planning, supervised administration, and follow-up monitoring.
Patients can expect the process to begin with an evaluation. The provider reviews depression history, previous medication trials, current symptoms, safety factors, and whether SPRAVATO may be an appropriate next step.
| Step | Patient pathway |
|---|---|
| Request evaluation | The patient contacts Lotus to ask about SPRAVATO Treatment. |
| Clinical review | The provider reviews depression history, prior medications, current symptoms, and safety factors. |
| Candidacy discussion | The patient learns whether SPRAVATO may fit their case. |
| REMS and insurance steps | Required enrollment, monitoring, scheduling, and coverage review are discussed. |
| Treatment planning | If appropriate, treatment sessions are scheduled with transportation planning. |
| Monitoring and follow-up | Symptoms, side effects, blood pressure, alertness, and treatment response are reviewed over time. |
Lotus Psychiatry & Wellness is led by Mustafa Pirzada, M.D., who is a board-certified child, adolescent, and adult psychiatrist and Diplomate of the American Board of Psychiatry & Neurology. Patients should contact the office to confirm current SPRAVATO provider availability, evaluation requirements, scheduling, and treatment steps.
Who May Qualify for SPRAVATO Treatment?
SPRAVATO Treatment may be considered for adults with depression who have not had enough improvement from previous antidepressant treatment. For treatment-resistant depression, the current prescribing information lists SPRAVATO for adults as monotherapy or in conjunction with an oral antidepressant.
| Evaluation factor | Why it matters |
|---|---|
| Depression diagnosis | The provider needs to confirm whether symptoms and diagnosis fit an approved use. |
| Medication history | Prior antidepressant response is central to candidacy. |
| Current symptoms | Severity, duration, safety risks, and daily functioning affect the treatment plan. |
| Medical history | Blood pressure, vascular history, neurological history, pregnancy status, and other risks matter. |
| Substance use history | SPRAVATO has abuse and misuse warnings, so this must be reviewed. |
| Current medications | Some medications may affect sedation, blood pressure, alertness, or safety monitoring. |
| Transportation plan | Patients cannot drive home after treatment. |
| Insurance requirements | Coverage may require documentation of diagnosis and prior treatment attempts. |
SPRAVATO is not approved for pediatric patients. The prescribing information includes pediatric and young adult antidepressant-related warning language, so age and safety screening matter before treatment.
What Is Treatment-Resistant Depression
Treatment-resistant depression, often shortened to TRD, usually refers to depression that has not improved enough after adequate depression and anxiety treatment attempts.
This does not mean a person has failed treatment. It means depression has not responded well enough to treatments already tried. A provider may need to review medication names, doses, duration, side effects, therapy history, hospitalizations, safety concerns, and current symptoms before recommending next steps.
SPRAVATO may be one option among several advanced depression treatment paths. Other options may include medication changes, psychotherapy, NeuroStar TMS, ECT, higher levels of care, or another plan depending on the person's clinical situation.
How SPRAVATO Works
SPRAVATO contains esketamine, which is related to ketamine but is not the same as compounded ketamine products. The SPRAVATO REMS identifies SPRAVATO as a non-competitive NMDA receptor antagonist.
Traditional antidepressants often work through serotonin, norepinephrine, or dopamine pathways. Esketamine is connected to the glutamate system and NMDA receptor activity. The precise mechanism of action in major depressive disorder is not fully known.
A safer patient explanation is this: SPRAVATO acts on a different brain pathway than many standard antidepressants, which is why it may be considered after previous antidepressant treatment has not helped enough.
What Happens During a SPRAVATO Treatment Session?
SPRAVATO is administered in a healthcare setting. The patient self-administers the nasal spray under direct observation of a healthcare provider and is monitored afterward. The prescribing information states that SPRAVATO must be administered under direct healthcare provider supervision and includes post-administration observation.
| Step | What happens |
|---|---|
| Evaluation | The provider reviews diagnosis, prior treatment, safety factors, and goals. |
| REMS enrollment | Patients treated in outpatient settings must be enrolled in the SPRAVATO REMS. |
| Preparation | Patients may be instructed to avoid food for at least 2 hours and liquids for at least 30 minutes before treatment. |
| Administration | The patient self-administers the nasal spray under provider observation. |
| Monitoring | The patient remains in the healthcare setting for at least 2 hours. |
| Discharge review | The provider decides when the patient is clinically stable and ready to leave. |
| Transportation | The patient must arrange a ride home and avoid driving until the next day after restful sleep. |
This process is one of the biggest differences between SPRAVATO and typical take-home medications.
SPRAVATO Treatment Schedule
For adult treatment-resistant depression, the current prescribing information describes an induction phase of twice-weekly treatment during weeks 1 through 4, followed by once-weekly treatment during weeks 5 through 8, then every 2 weeks or once weekly from week 9 onward based on response and tolerability.
| Phase | Typical pattern |
|---|---|
| Evaluation phase | Review symptoms, history, eligibility, risks, and coverage. |
| Induction phase | More frequent treatment sessions during the first 4 weeks. |
| Early maintenance | Weekly sessions may be used during the next phase. |
| Ongoing maintenance | Frequency may decrease based on response and provider judgment. |
| Progress review | The provider evaluates benefit, side effects, safety, and continued need. |
The exact schedule should be confirmed during evaluation. Treatment plans depend on diagnosis, response, tolerability, safety, insurance rules, and provider judgment.
Safety, REMS, and Monitoring Requirements
SPRAVATO is available only through a restricted distribution program called the SPRAVATO REMS because of risks including sedation, dissociation, respiratory depression, abuse, and misuse. Healthcare settings must be certified in the REMS, and patients treated in outpatient healthcare settings must be enrolled in the program.
SPRAVATO is intended only for use in a supervised healthcare setting. It must not be dispensed directly to patients for home use. The prescribing information requires monitoring by a healthcare provider for at least 2 hours after administration.
| Monitoring area | Why it matters |
|---|---|
| Sedation | SPRAVATO can cause sleepiness or reduced alertness. |
| Dissociation | Patients may feel disconnected from themselves, their thoughts, or surroundings. |
| Respiratory status | Respiratory depression has been identified as a serious risk in safety materials. |
| Blood pressure | Blood pressure may increase and may need repeated checks. |
| Clinical stability | The provider decides when the patient is ready to leave. |
| Abuse and misuse risk | SPRAVATO is a Schedule III controlled substance. |
| Transportation readiness | Patients need a ride home after each session. |
Patients should contact Lotus Psychiatry & Wellness to confirm current treatment availability, eligibility steps, REMS-related requirements, and scheduling.
Side Effects and Risks to Discuss Before Treatment
The most common side effects of SPRAVATO for treatment-resistant depression include dissociation, dizziness, nausea, sedation, vertigo, reduced sensation or numbness, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache.
Serious risks include sedation, dissociation, respiratory depression, abuse and misuse, increased blood pressure, cognitive impairment, impaired ability to drive or operate machinery, and antidepressant-related suicidal thoughts and behavior warnings in pediatric and young adult patients. SPRAVATO is not approved for pediatric patients.
SPRAVATO is contraindicated in patients with aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage, or hypersensitivity to esketamine, ketamine, or any excipients. These contraindications should be reviewed during the SPRAVATO evaluation before treatment is considered.
Patients should tell the provider about high blood pressure, heart or blood vessel problems, stroke history, brain injury, psychosis, substance use concerns, pregnancy status, current medications, and any previous reaction to ketamine or esketamine.
For a more detailed explanation of timing, dissociation, sedation, blood-pressure changes, driving restrictions, and longer-term safety considerations, read our guide to SPRAVATO side effects and risks .
Benefits and Realistic Expectations
SPRAVATO may help some eligible adults with depression that has not improved enough with previous treatment. The current indication allows adult TRD treatment as monotherapy or with an oral antidepressant.
Expectations should stay realistic. SPRAVATO is not a guaranteed cure, and results vary. The prescribing information says treatment benefit should be evaluated after the induction phase to determine the need for continued treatment.
For adults with MDD and acute suicidal ideation or behavior, the prescribing information states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not remove the need for hospitalization if clinically warranted.
SPRAVATO vs Ketamine Therapy
SPRAVATO and ketamine therapy should not be treated as the same service. SPRAVATO is esketamine nasal spray with specific FDA-approved depression-related indications and REMS requirements.
The FDA warns that compounded ketamine products are not FDA-approved for psychiatric disorders, and home use of compounded ketamine products adds risk because onsite healthcare monitoring is not available.
| Topic | SPRAVATO | Compounded ketamine products |
|---|---|---|
| Active ingredient | Esketamine nasal spray | Ketamine in compounded forms |
| FDA status | FDA-approved for specific adult depression-related indications | Not FDA-approved for psychiatric disorders |
| Setting | Certified healthcare setting under REMS | May vary by provider, platform, or product model |
| Monitoring | At least 2 hours after treatment | FDA has warned about risks when used without onsite monitoring |
| Home use | Not dispensed directly to patients for home use | Some compounded products may be marketed for at-home use |
| Main safety issue | REMS-required monitoring for sedation, dissociation, respiratory depression, abuse, and misuse | FDA has not evaluated compounded products for safety, effectiveness, or quality before marketing |
Cost, Insurance, and Access
SPRAVATO cost depends on insurance plan rules, medical necessity criteria, diagnosis, prior medication documentation, copays, deductibles, treatment frequency, and whether prior authorization is required.
Lotus Psychiatry & Wellness accepts several insurance plans, but SPRAVATO coverage should still be verified for each patient because benefits can vary by plan, diagnosis, documentation, deductible, copay, coinsurance, and authorization status.
| Requirement | Why it may be needed |
|---|---|
| Depression diagnosis documentation | Insurance may require diagnostic confirmation. |
| Prior antidepressant history | TRD criteria often require previous medication attempts. |
| Clinical notes | The plan may ask for documentation of symptoms and prior treatment. |
| Prior authorization | Approval may be required before treatment starts. |
| Transportation plan | Patients cannot drive themselves home after treatment. |
| Out-of-pocket estimate | Copay, deductible, and coinsurance can vary. |
Patients should contact Lotus Psychiatry & Wellness directly for insurance verification and out-of-pocket estimates before starting treatment planning.
When SPRAVATO May Not Be the Right First Step
SPRAVATO may not be appropriate for every patient. It may not be the right first step if a person has an immediate safety emergency, requires hospitalization, has a contraindication, has uncontrolled medical risks, cannot arrange transportation, or needs another level of care before outpatient treatment.
SPRAVATO does not remove the need for hospitalization when clinically warranted, even if symptoms improve after an initial dose.
If a person is in immediate danger, may harm themselves, or may harm someone else, they should call 988, call 911, or go to the nearest emergency department.
Why Choose Lotus Psychiatry & Wellness for SPRAVATO Treatment?
Lotus Psychiatry & Wellness is a psychiatry and wellness clinic serving Boca Raton, Coral Springs, Parkland, and nearby South Florida communities. The clinic provides psychiatric evaluation, therapy-related services, medication management, NeuroStar TMS, SPRAVATO, GeneSight, and wellness services through its care model.
For SPRAVATO Treatment, the psychiatric setting matters. Patients may need diagnostic review, medication history review, safety screening, REMS-related steps, insurance documentation, transportation planning, monitoring, and follow-up care.
Boca Raton, FL 33431
Coral Springs, FL 33067
Request a SPRAVATO Treatment Evaluation
SPRAVATO Treatment may be an option for eligible adults with depression that has not improved enough after prior treatment, but the decision requires a professional evaluation. Treatment has strict safety requirements, monitoring rules, transportation restrictions, and REMS-related steps.
Patients in Boca Raton, Coral Springs, Parkland, and nearby South Florida communities can contact Lotus Psychiatry & Wellness to ask whether SPRAVATO Treatment may fit their treatment history and current symptoms. The safest next step is not self-diagnosis. It is a supervised evaluation with a qualified mental health provider.
FAQs About SPRAVATO Treatment
WARNING: SEDATION, DISSOCIATION; ABUSE AND MISUSE; and SUICIDAL THOUGHTS AND BEHAVIORS
- Risk for sedation and dissociation after administration. Monitor patients for at least two hours after administration
- Potential for abuse and misuse. Consider the risks and benefits of using SPRAVATO® prior to use in patients at higher risk of abuse. Monitor for signs and symptoms of abuse and misuse
- SPRAVATO® is only available through a restricted program called the SPRAVATO® REMS
- Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. SPRAVATO® is not approved for use in pediatric patients